Large Pharma licensing from China hits record 28% mark in 2024, GlobalData reveals
GlobalData’s latest analysis reveals a significant shift in the pharmaceutical landscape: in 2024, large pharmaceutical companies sourced an unprecedented 28% of their innovative drug candidates through licensing agreements with Chinese biopharma firms—the highest proportion ever recorded.